V. Patel PH.D - Chairman, President and Chief Executive Officer
Dr. Mahesh V. Patel has more than 20 years of technology and
product development experience in the area of drug discovery support, drug
delivery and product line extensions. Prior to co-founding Lipocine in 1997,
Dr. Patel led drug delivery research and development at Pharmacia and Upjohn
in Kalamazoo, MI. He received his MS in Physical Pharmacy at the University
of Cincinnati and his PhD in Pharmaceutics from the University of Utah. His
areas of expertise include strategic planning, technology
assessment/development, technical management and product research and
Brown - Executive Vice President and Chief Financial Officer
Mr. Morgan Brown has more than 20 years of finance and
accounting experience with the last thirteen years servicing biotechnology,
pharmaceutical, medical device and clinical research companies. Prior to
joining Lipocine, Mr. Brown served in a similar capacity at Innovus
Pharmaceuticals, Inc. (OTCBB: INNV), an emerging pharmaceuticals company, at
World Heart Corporation (NASDAQ: WHRT), a medical device company, and
Lifetree Clinical Research, a clinical research organization. During Mr.
Brown's tenure at World Heart Corporation, he was involved in numerous
financings in addition to the ultimate sale of World Heart Corporation to
Heartware International Inc. (NASDAQ: HTWR). Previously he worked for NPS
Pharmaceuticals Inc. (NASDAQ: NPSP), a biotechnology company where he served
as Vice President Finance and Treasurer. During his tenure at NPS
Pharmaceuticals, Inc., Mr. Brown was involved in numerous financings as well
as merger and acquisition activities. Before NPS Pharmaceuticals, Inc., Mr.
Brown worked for KPMG LLP in Salt Lake City for over seven years and managed
multiple audit engagements, servicing private and publicly owned clients.
Mr. Brown is a licensed certified public accountant in Utah. Mr. Brown
earned a Master of Science degree in Business Administration from the
University of Utah and a Bachelor of Science degree in Accounting from Utah
Bass - Excecutive Vice President and Chief Commercial Officer
Mr. Bass brings over 20 years of pharmaceutical and biotech
sales, marketing, market access and operations experience to Lipocine. He
has a proven track record of launching new products, improving operating
performance and driving value across a broad range of therapeutic categories
which includes men’s health. Most recently, he was Lipocine’s Vice
President of Market Access. Prior to joining Lipocine, Mr. Bass served as
the Vice President of Market Access at Merz. Previously, he held multiple
senior leadership roles in marketing and market access over a 9 year period
at Johnson & Johnson. Before Johnson & Johnson, Mr. Bass spent 7
years at Pfizer and held positions of increasing responsibility in sales and
operations. He received his bachelor’s degree in Biology from Brandeis
University in Waltham, MA.
Matilla - Exceutive Vice President and Chief Business Officer
Dr. Mattila brings over 25 years of business development,
commercial and general management experience to Lipocine. Prior to joining
Lipocine, Dr. Mattila served as CBO of iCeutica Operations Inc. and as
President and CEO of LZ Therapeutics, Inc. Prior to these positions, Dr.
Mattila was Executive Vice President of Business Development, Product
Development and Technical Operations at Auxilium Pharmaceutical, Inc and
President of Orion Pharma, where under his leadership several innovative
products were developed, partnered and commercialized for global markets.
Dr. Mattila has negotiated and closed over 50 business agreements, including
licensing, co-marketing, collaboration and product acquisition arrangements.
He received his M.D. and Ph.D. in Pharmacology from the University of
Helsinki Medical School and an M.B.A. from the Helsinki School of Economics.
675 Arapeen Drive
Salt Lake City, UT 84108
feature stock reports are intended to be stock ideas, not recommendations.
Please do your own research before investing. It is crucial that you at
least look at current SEC filings and read the latest press releases.
Information contained in this report was extracted from current documents
filed with the SEC, the company website and other publicly available sources
deemed reliable. For more information see our disclaimer section, a link of
which can be found on our website. This document contains forward-looking
statements, particularly as related to the business plans of the Company,
within the meaning of Section 27A of the Securities Act of 1933 and Sections
21E of the Securities Exchange Act of 1934, and is subject to the safe
harbor created by these sections. Actual results may differ materially from
the Company's expectations and estimates. The information provided in this
report is not intended for distribution to, or use by, any person or entity
in any jurisdiction or country where such distribution or use would be
contrary to law or regulation or which would subject us to any registration
requirement within such jurisdiction or country.
SmallCapReview. All rights reserved. SCR is not a Registered Broker/Dealer
or Financial Advisor. All materials presented on our website and individual
reports released to the public through this website, e-mail or any other
means of transmission are not to be regarded as investment advice and
are only for informative purposes. Before making a purchase or sale of any
securities featured on our web site or mentioned in our reports, we
strongly encourage and recommend consultation with a registered
securities representative. This is not to be construed as a
solicitation or recommendation to buy or sell securities. Past
performance of our profiled stocks is not indicative of future results. The
profile and opinions expressed herein are expressed as of the date the
profile is posted on site and are subject to change without notice. No
investor should assume that reliance on the views, opinions or
recommendations contained herein will produce profitable results.
SmallCapReview may hold positions in securities mentioned herein, and may
make purchases or sales in such securities featured on our website or within
our reports In order to be in full
compliance with the Securities Act of 1933, Section 17(b), SCR will disclose
in it's disclaimer, what, if any compensation was received for our
efforts in researching, presenting and disseminating this information to our
subscriber database and featuring the report on the SmallCapReview website. SmallCapReview
has not been compensated for its efforts with regards to Lipocine. As
with any stock, companies we select to profile involve a degree of
investment risk and volatility, particularly small-caps. All investors are
cautioned that they may lose all or a portion of their investment if they
decide to make a purchase in any of our profiled companies.
encourage our readers to invest carefully and read the investor information
available at the web sites of the Securities and Exchange Commission (SEC)
and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com
. Readers can review all public filings by companies at the SEC's EDGAR
page. The NASD has published information on how to invest carefully at its